Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy

Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy

Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responder...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sara De Biasi, Lara Gibellini, Domenico Lo Tartaro, Simone Puccio, Claudio Rabacchi, Emilia M. C. Mazza, Jolanda Brummelman, Brandon Williams, Kelly Kaihara, Mattia Forcato, Silvio Bicciato, Marcello Pinti, Roberta Depenni, Roberto Sabbatini, Caterina Longo, Massimo Dominici, Giovanni Pellacani, Enrico Lugli, Andrea Cossarizza
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/5dde8cd7955f4749b3113f29084ac913
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responders have more MAIT cells expressing CXCR4 and granzyme B.

Ejemplares similares